WBP 216

Drug Profile

WBP 216

Alternative Names: Long-acting anti-IL6 antibody - MedImmune; MEDI-5117; WBP216

Latest Information Update: 23 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MedImmune
  • Developer MedImmune; WuXi AppTec
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders
  • No development reported Inflammation
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 18 Jan 2017 China Food and Drug Administration approves IND application for WBP 216 in Rheumatoid arthritis
  • 18 Jan 2017 WuXi-MedImmune plans a phase I trial for Rheumatoid arthritis in China
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in China (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top